Although hypertrophic scars (HTSs) and keloids are challenging problems, their pathogenesis is not well understood, making therapy difficult. We showed that matrix metalloproteinase (MMP)-1 expression was downregulated in HTS compared with normal skin from the same patients, whereas type 1 and 3 collagen and transforming growth factor-b (TGF-b) were upregulated. These differences, however, were not seen in cultured fibroblasts, suggesting the involvement of microenvironmental factors in the pathogenesis of HTS. Fibroblast growth factor-2 (FGF-2) highly upregulated the expression of MMP-1 and hepatocyte growth factor (HGF) in both HTS-derived and control fibroblasts; the upregulation was reversed by extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) inhibitors. An animal study using human HTS tissue implanted into nude mice indicated that controlled-release FGF-2 resulted in significantly less weight and decreased hydroxyproline content in HTS. Degradation of collagen fibers in FGF-2-treated HTS was also confirmed histologically. Western blotting showed that FGF-2-treated HTS expressed significantly higher MMP-1 protein than control. Decreased MMP-1 expression may be an important transcriptional change in HTS, and its reversal as well as upregulation of HGF by FGF-2 could be a new therapeutic approach for HTS.
Hypertrophic scars (HTSs) are a challenging problem. Burns, traumatic injuries, and surgical procedures produce exuberant scarring that is not only aesthetically displeasing, but can also be functionally disabling, causing patients both physical and psychological distress. 1, 2 HTSs are linear or widespread in shape and generally red, elevated, and sometimes pruritic. 3 The presence of nodules in HTS is caused by a high density of cells and collagen. Besides collagen, the major components of HTS are myofibroblasts, which are differentiated fibroblasts found in granulation tissue. A large proportion of myofibroblasts expresses smooth muscle proteins such as a-smooth muscle actin (a-SMA). 4 HTS can be distinguished from keloids, the other major form of excessive scarring seen in humans. There is stronger evidence for genetic predisposition in keloid formation than in HTS. [5] [6] [7] Keloids are characterized by overgrowth of fibrosis beyond the boundaries of the original injury, whereas HTS remains within the boundaries of the original wound and increases in size by pushing out the edge of the scar. 8 Keloids and HTS can also be distinguished by established histopathological criteria, including differences in collagen density and orientation, vascularity, and other factors. 9 a-SMAexpressing myofibroblasts are generally absent in keloids. 4 Apart from many differences, both HTS and keloid lesions likely represent aberrations in the fundamental processes of wound healing, causing excessive collagen production by fibroblast activity. 8, 10 Most current research on HTS and keloids involves the evaluation of protein factors that control a complex series of wound healing processes in a highly systematic manner.
There are numerous therapeutic methods for HTS or keloids that have been described, including compression therapy, gel sheeting, corticosteroid injections, surgical excision, radiation therapy, laser therapy, cryotherapy, or combinations of these, although there is no single definitive treatment modality. 11 One of the most common treatments is intralesional injection of triamcinolone, which was shown to increase the production of fibroblast growth factor-2 (FGF-2; basic fibroblast growth factor) and decrease the production of transforming growth factor-b (TGF-b) by human dermal fibroblasts. 12 We previously demonstrated that FGF-2 released at the time of adipose injury promotes hepatocyte growth factor (HGF) secretion from adipose-derived stromal cells and/or fibroblasts and inhibits post-injury fibrogenesis. 13 HGF has anti-fibrogenic effects in various organs, including heart, 14 liver, 15 and kidney 16 and antagonizes the profibrogenetic action of TGF-b by intercepting Smad signal transduction through diverse mechanisms. 17 There are also some reports on the anti-scarring effects of FGF-2, [18] [19] [20] including clinical use. Post-operative administration of FGF-2 inhibits hypertrophy and widening of scars without any serious side effects. 21 These results suggested that FGF-2 treatment during wound healing may contribute to prevention of HTS and keloid formation.
Despite the possible preventive effect of FGF-2, its therapeutic potential for HTS and keloid formation has not been evaluated. We investigated whether FGF-2 has therapeutic effects on long-standing HTS. For this purpose, we comparatively evaluated the in vitro effects of FGF-2 on fibroblasts isolated from human HTS and normal skin as well as therapeutic effects on nude mouse models in which human HTS was subcutaneously implanted.
MATERIALS AND METHODS Patients and Experimental Protocol
Nine patients (six females and three males, age 17-67 years) underwent surgical resection of HTS (Table 1) . Normal skin adjacent to the scar excised during surgery was used as the control. All human and animal studies have been approved by the institutional review board, and informed consent was obtained from each patient.
Cell Culture
Fibroblasts were obtained from explant cultures of normal skin and scar samples. Primary cells were cultured for 7-10 days and were defined as 'Passage 0'. Cells were passaged every week by trypsinization. Cells at passages 1-3 were used in the experiments. The culture medium was Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. The medium was replaced every 3 days. For gene expression analysis by real-time PCR, cells were cultured with or without FGF-2 (10 ng/ml) for 5 days. For the signal inhibition assay, scar-derived fibroblasts were cultured in the culture medium containing each inhibitor (ERK inhibitor, U0126; p38 protein inhibitor, SB202190; JNK inhibitor, SP600125; all from Calbiochem, La Jolla, CA, USA) at 10 mM for 6 or 24 h. Human recombinant FGF-2 was kindly supplied by Kaken Pharmaceutical (Tokyo, Japan).
Quantitative Real-Time RT-PCR Total RNA was isolated from the samples using an RNeasy Mini Kit (Qiagen, Hilden, Germany) followed by reverse transcription. Real-time PCR was performed with the ABI 7700 sequence detection system and a SYBR Green PCR Master Mix (both from Applied Biosystems, Foster City, CA, USA). The primer sequences are shown in Table 2 . Expression levels were calculated by the comparative C T method with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an endogenous reference gene.
Scar Transplantation Model
HTS tissue was cut into small discoidal fragments (5 mm in diameter and 3 mm thickness) after the overlying skin and the subcutaneous fat were removed. A 7-mm centerline incision was made on the back of 6-week-old male nude mice. A discoidal HTS was then transplanted subcutaneously on the lateral side of the back. Two weeks after transplantation, 10 mg FGF-2 or vehicle incorporated into controlledrelease gelatin microspheres 22, 23 was injected into the graft. Four weeks after administration of FGF-2 or vehicle, the grafts were harvested and stained with hematoxylin and 
Quantification of Hydroxyproline
Collagen content was analyzed by measuring hydroxyproline content as described previously. 24 Briefly, the samples were homogenized in 5 ml of 6 N HCl and hydrolyzed at 110 1C for 24 h. In all, 500 ml of 10% alanine solution and 1 ml of potassium borate buffer were added to the hydrolysate, which was oxidized with 1 ml of 0.2 M chloramine T solution for 25 min. The oxidation was stopped with 3 ml of 3.6 M sodium thiosulfate, and 5 ml of toluene was added to the sample, which was centrifuged. The toluene layer was removed and boiled for 30 min. Toluene was added to the materials, and the solution was centrifuged. The toluene extract was incubated with 1 ml of Ehrlich's reagent for 30 min, and the absorbance was read at 560 nm. The amount of hydroxyproline in the sample was calculated by comparison with a standard hydroxyproline curve.
Western Blotting
After the samples were homogenized in 500 ml of RIPA lysis buffer (Santa Cruz Biotechnology, Santa Cruz, CA, USA), the 
RESULTS

Gene Expression in HTS and Normal Skin
Analysis of gene expression in fresh tissues indicated that type 1 and 3 collagen and TGF-b were highly upregulated in HTS compared with normal skin. Average expression of a-SMA and HGF was higher in HTS, although the differences were not statistically significant. In contrast, MMP-1 mRNA expression was downregulated in HTS to less than half the levels in normal skin (Figure 1a) . Interestingly, however, these differences in gene expression were not seen in cultured fibroblasts between HTS and normal skin, except type 3 collagen and MMP-1, which were downregulated in HTSderived fibroblasts (Figure 1b ).
FGF-2 Effects on HTS-Derived Fibroblasts and Related
Signaling Pathways FGF-2 strongly promoted cell proliferation of both HTSderived and normal skin-derived fibroblasts. The proliferation promoting effect of FGF-2 was clearly inhibited by a JNK inhibitor (Figure 2a) . Morphologically, fibroblasts cultured with FGF-2 were smaller in size compared with those cultured in control medium or the JNK inhibitor, though there were no differences between HTS and normal skin (Figure 2b ). Real-time PCR indicated that FGF-2 downregulated the expression of type 1 and 3 collagen in HTS-derived fibroblasts ( Figure 3 ). FGF-2 also downregulated a-SMA mRNA expression in normal skin-derived fibroblasts. Most interestingly, FGF-2 highly upregulated gene expression of HGF and MMP-1 in both HTS-derived and normal skin-derived fibroblasts.
To further analyze the signaling pathways related to the upregulation of HGF and MMP-1 mRNA expression in HTSderived fibroblasts, a signal inhibition assay was performed with inhibitors of each of the mitogen-activated protein kinase (MAPK) pathways (ERK, p38, and JNK inhibitors). The administration of ERK inhibitor for both 6 and 24 h inhibited the upregulation of both HGF and MMP-1, and JNK inhibitors inhibited the upregulation of both HGF and MMP-1 at 24 h, whereas the p38 inhibitor had no effect on mRNA expression of either HGF or MMP-1 in HTS-derived fibroblasts (Figure 4 ).
Therapeutic Effects of FGF-2 Treatment on HTS in Animal Models
Human HTS samples were subcutaneously transplanted into the back of nude mice and harvested 4 weeks after FGF-2 treatment (Figure 5a ). The weight of the human HTS samples was significantly smaller in the FGF-2-treated group than in the vehicle-treated group (Figure 5b) . Histological analysis of the samples showed that transplanted HTS tissue was preserved well with dense collagen fibers and was distinguished clearly from surrounding tissues in the recipient site in the vehicle-treated group. In contrast, samples treated with FGF-2 had less dense collagen fibers, and the HTS tissue border with the surrounding tissue was unclear (Figure 5c ).
Quantification of hydroxyproline indicated that collagen content was also significantly less in the FGF-2-treated group (Figure 6a ). Western blotting showed that MMP-1 protein expression in HTS tissue was significantly increased by FGF-2 
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H Eto et al treatment (Figure 6b ). These changes in the FGF-2 group were also confirmed by Azan staining (data not shown), suggesting degradation of collagen fibers.
DISCUSSION
The therapeutic effects of FGF-2 on HTSs or keloids have not been demonstrated before, although some studies have suggested prophylactic efficacy on excessive fibrogenesis during wound healing. In this study, we evaluated the therapeutic potential of FGF-2 for long-standing HTS and analyzed the underlying mechanism. Gene expression analysis of fresh dermal tissues in HTS and intact skin showed that HTS tissue had significantly higher mRNA expression of type 1 and type 3 collagen, important components of the extracellular matrix in HTS, 25 and TGF-b, which is a pathogenic mediator in tissue fibrosis; 26 but the expression of MMP-1, a collagenase that mainly digests interstitial collagen type 1 and 3, was significantly lower; these results are consistent with previous reports analyzing tissue fibrosis. 27, 28 Gene expression of other collagenases, MMP-8 and MMP-13, were preliminary measured in fresh samples, but expression level of them were nearly at an undetectable level (data not shown).
On the other hand, gene expression patterns of HTSderived cultured fibroblasts were almost the same as those of normal-skin derived cultured fibroblasts, except for lower expression of type 3 collagen and MMP-1, although keloidderived fibroblasts were previously reported to differ from normal fibroblasts in expression of a large number of genes. 29 Thus, HTS-derived cultured fibroblasts in this study lost many of the differences from normal dermal cells in gene expression (upregulation of collagen type 1 and 3, and TGF-b), suggesting possible involvement of environmental factors in the pathogenesis of HTS. However, the differences between the HTS whole tissue and HTS-derived cultured fibroblasts might be due to the other cell types residing in the whole tissue. In addition, slightly different responses to FGF-2 between HTS-derived fibroblasts and normal skin-derived fibroblasts may suggest involvement of genetic factors. Other factors regulating MMPs, such as TIMPS, might be involved, though they were not investigated in this study.
Previous studies have shown that HGF and TGF-b are involved in the pathogenesis of fibrous diseases of various organs, and many challenges to elucidate their roles and 16, 17 TGF-b1 is a positive regulator of fibrosis; it activates fibroblasts to become myofibroblasts and to produce large amounts of matrix proteins in various organs. 17 On the other hand, HGF inhibits the TGF-b1-mediated activation of myofibroblasts and reverses fibrogenetic processes by upregulating MMP-1.
15,28 Both upregulated TGF-b1 and decreased expression of HGF were thought to be involved in renal fibrosis. 27 In this study, gene expression of HGF and MMP-1, which both have anti-fibrogenetic activity, was markedly upregulated by FGF-2 in HTS-derived and normal fibroblasts. Unlike MMP-1, upregulation of HGF mRNA expression at 6 or 24 h (Figure 4 ) are much lower compared to at 5 days (Figure 3) , suggesting indirect effects of FGF-2 on 30, 31 and fibroblasts. 32 It was also shown that upregulation of MMP-1 mRNA in osteoblasts is mediated by the MAPK pathway and completely abrogated by MAPK phosphatase (inactivates ERK ¼ JNK4p38 MAPK), 33 although the signaling mechanism in dermal fibroblasts remains to be elucidated. Using selective inhibitors of each of three signaling pathways of MAPK cascades (ERK inhibitor U0126, p38 protein inhibitor SB202190, and JNK inhibitor SP600125), we showed that FGF-2-induced upregulation of both HGF and MMP-1 mRNA expressions was abrogated by the ERK inhibitor or the JNK inhibitor in HTS-derived fibroblasts. ERK pathway seemed to be more crucial for the transcriptional activation of HGF and MMP-1, because only ERK inhibitor showed the inhibitory effect at an early stage. FGF-2 antagonizes myofibroblast activation via the ERK signaling pathway in cultured aortic valvular interstitial cells and aortic smooth muscle cells. 34, 35 To evaluate the therapeutic effects of FGF-2 on reducing scar tissue, we administered controlled-release recombinant FGF-2 to human HTS tissue implanted subcutaneously into the back of nude mice. Because no HTS or keloid develops in non-human animals without intervention, an ideal animal model of HTS has been unavailable, hampering relevant research. Recently, several groups attempted to observe scar formation in animal models. Yang et al 36 prepared an HTS model by transplanting full-thickness human skin onto the back of nude mice, whereas Chin et al 37 stretched the murine skin with a computer-controlled device. These models were expected to reproduce scar formation process, not established HTS or keloid. In this study, we sought to evaluate a therapeutic effect on long-standing HTSs or keloids, and developed another murine model in which human HTS tissue was implanted before treatment. Previous reports also used implantation of HTS tissue, but they transplanted considerably large specimens bilaterally on the backs of nude mice, 38 ,39 whereas we processed the HTS tissue into small discoidal pieces and implanted only one piece into the left side of the back to avoid systemic or diffusive effects of FGF-2 to the control side. The scar weight after transplantation was educed even in the vehicle-treated group as reported previously, [38] [39] [40] although our reduction rate was larger perhaps because of the smaller size of the implanted tissue.
Our animal experiment results clearly indicated a therapeutic effect of FGF-2 in HTS; FGF-2 significantly decreased the scar weight and amount of collagen. Histological observation clearly indicated that collagen fibers in HTS had been degraded following FGF-2 treatment, and the mechanism likely involved increased MMP-1 mRNA and protein. FGF-2-treated tissue showed marked increase of infiltrating cells, presumably inflammatory cells; FGF-2 is primarily released in the first phase of wound healing upon injury, and thus FGF-2 injection to the tissue appears to trigger a series of subsequent wound healing process without actual wounding. 41 Clinical use of FGF-2 for HTS treatment may be readily achievable, because recombinant FGF-2 protein is an approved therapeutic product (Fiblast spray s , Kaken Pharmaceuticals) in Japan. It is topically used to accelerate wound healing in chronic skin ulcers. 42 As a growth factor therapy, however, we must optimize the concentration and administration method. Because of the short in vivo half-life of growth factors in solution, controlled release of growth factors is needed for full effectiveness. We used gelatin hydrogel microspheres for controlled release of FGF-2 over an extended period of time as in previous studies. 22, 23, 43 Sequential administration of FGF-2 may be another way to achieve therapeutic effectiveness. The concentration is also important because a high dose of FGF-2 may cause an excessive inflammatory response. 23 Further study is needed to optimize the parameters of FGF-2 therapy for each therapeutic purpose.
In conclusion, we provide evidence of a new therapeutic strategy, FGF-2 administration for the treatment of established HTS. Differences in gene expression between HTS and normal skin obtained from the same patients were almost diminished in cultured fibroblasts, suggesting the importance of microenvironmental factors in the pathogenesis of HTS. Pathological changes in HTS included downregulation of MMP-1 mRNA. FGF-2 increased MMP-1 and HGF expression in HTS via either ERK or JNK signaling pathway, which may be the responsible mechanism for FGF-2 effects on HTS. The efficacy of treatment using controlledrelease FGF-2 was demonstrated in animal models with implanted human HTS. 
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